MedTrace Logo

L-arginine Treatment in Mild Hypertension

NCT02894723 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-09-09

No results posted yet for this study

Summary

Essential Hypertension is characterized by endothelial dysfunction due to reduced nitric oxide (NO) bioavailability. Impairment in nitric oxide-mediated vasodilatation in human brachial, coronary, and renal arteries has been demonstrated in patients with essential hypertension. Administration of L-arginine, a NO substrate yeld controversial results.

The purpose of the present study, double blind and matched for age, sex and body mass index (BMI), is to assess the efficacy of L-arginine treatment on blood pressure (BP) control and arterial stiffness in patients with stage1 hypertension.

Conditions

Interventions

DIETARY_SUPPLEMENT

L-arginine

30 ml arginoline contains 5 gr l-arginine

DIETARY_SUPPLEMENT

syrup

The same bottle of the experimental group, but without l-arginine

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Eduardo Podjarny, MD · Clalit Health Services

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-02-28
Completion
2017-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02894723 on ClinicalTrials.gov